Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AEON | PRESS-RELEASE | bullish | 6/10 | AEON Biopharma released expanded primary structure and preliminary disulfide bond data for its ABP-450 biosimilar candid | Aug 19, 2026 |
| PLRX | PRESS-RELEASE | bullish | 4/10 | Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refract | Aug 18, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced it is finalizing a clinical trial protocol and conducting a feasibility assessment for a Fir | Aug 18, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc invested C$2.7 million in its majority-owned subsidiary NeuroThera's non-brokered private placement, which rais | Aug 18, 2026 |
| IMTX | PRESS-RELEASE | mixed | 6/10 | Immatics reported Q2 2026 earnings with a narrower-than-expected net loss per share of -$0.46 (€-0.46), beating consensu | Aug 18, 2026 |
| CHRS | PRESS-RELEASE | neutral | 4/10 | Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its remaining | Aug 17, 2026 |
| PLUR | PRESS-RELEASE | neutral | 4/10 | Pluri's majority-owned food-tech subsidiary, Ever After Foods (EAF), has acquired Fishway BV, a Belgian aquatic cell bio | Aug 17, 2026 |
| NSRX | PRESS-RELEASE | neutral | 5/10 | Nasus Pharma reported a net loss of $5.9M for H1 2026, widening from $1.3M in H1 2025, driven by increased R&D and G&A c | Aug 17, 2026 |
| KMDA | 6-K, PRESS-RELEASE | bullish | 6/10 | Kamada Ltd. reported record-high revenue and profitability for the first six months of 2026 and declared a cash dividend | Aug 17, 2026 |
| RADX | PRESS-RELEASE | bullish | 7/10 | Radiopharm Theranostics announced an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 tri | Aug 17, 2026 |
| NRXP | PRESS-RELEASE | neutral | 1/10 | NRx Pharmaceuticals, Inc. announced it will host a conference call on August 17 to discuss its Q2 2026 results. | Aug 17, 2026 |
| ADIL | PRESS-RELEASE | neutral | 4/10 | Adial Pharmaceuticals reported Q2 2026 results with a net loss of $52.0M ($11.25 per share), driven by a $46.2M non-cash | Aug 17, 2026 |
| FULC | PRESS-RELEASE | bullish | 8/10 | Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockh | Aug 17, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back | Aug 16, 2026 |
| HCM | PRESS-RELEASE | bullish | 8/10 | HUTCHMED announced positive Phase III SAFFRON trial results showing savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) s | Aug 16, 2026 |
| WLK | PRESS-RELEASE | neutral | 2/10 | Westlake Corporation declared a regular quarterly dividend of $0.533 per share, payable September 10, 2026. This is a ro | Aug 14, 2026 |
| BYSI | PRESS-RELEASE | neutral | 5/10 | BeyondSpring reported Q2 2026 net loss of $1.8M from continuing operations, essentially flat YoY, with no revenue. The k | Aug 14, 2026 |
| ATNM | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 14, 2026 |
| VVOS | PRESS-RELEASE | bearish | 6/10 | Vivos Therapeutics reported Q2 2026 revenue of $5.2M, up 35% YoY, but EPS of -$0.31 missed consensus of -$0.39 by 20.5%. | Aug 14, 2026 |
| TRAW | PRESS-RELEASE | bearish | 5/10 | Traws Pharma reported a Q2 2026 EPS of -$0.53, missing the consensus estimate of -$0.45 by 17.8%. The company had zero r | Aug 14, 2026 |
| CUE | PRESS-RELEASE | neutral | 4/10 | Cue Biopharma reported Q2 2026 net loss of $153.1M on revenue of $7.9M, well above consensus estimates on both lines, bu | Aug 14, 2026 |
| SXTP | PRESS-RELEASE | bearish | 5/10 | Sixty Degrees Pharmaceuticals reported Q2 2026 revenue of $208K (up 106% YoY) but a net loss of $2.40M ($0.90/share), mi | Aug 14, 2026 |
| HCWB | PRESS-RELEASE | bearish | 8/10 | HCW Biologics reported Q1 2026 EPS of $2.22, a 212.1% beat vs the -$1.98 consensus, but this is entirely due to a previo | Aug 14, 2026 |
| JSPR | PRESS-RELEASE | neutral | 5/10 | Jasper Therapeutics reported Q2 2026 EPS of -$0.10, a 94.3% beat vs the -$1.74 year-ago loss, but this is largely a mech | Aug 14, 2026 |
| SKYE | PRESS-RELEASE | bearish | 7/10 | Skye Bioscience announces a reverse merger with private UK biotech Redx Pharma, forming Fibrx Therapeutics focused on fi | Aug 14, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings (ELAB) reported Q2 2026 revenue of approximately $1.31M, up from $0 in the prior-year period and 92% seque | Aug 14, 2026 |
| CNTN | PRESS-RELEASE | neutral | 4/10 | Canton Strategic Holdings reported its first-ever operating revenue of $1.5M for Q2 2026, driven by its Canton Network S | Aug 14, 2026 |
| SLXN | PRESS-RELEASE | bearish | 5/10 | Silexion Therapeutics reported Q2 2026 net loss of $3.6M (vs $2.5M a year ago) and EPS of -$8.50, far below the -$2.12 c | Aug 14, 2026 |
| VVOS | PRESS-RELEASE | neutral | 1/10 | Vivos Therapeutics, Inc announced it will report its Q2 2026 results on August 14, 2026. | Aug 14, 2026 |
| BCAX | PRESS-RELEASE | neutral | 2/10 | Bicara Therapeutics announced an inducement stock option grant to new CFO Jennifer Larson, effective August 12, 2026, as | Aug 14, 2026 |